 Biotech stocks bad investment reputations often not always come from failed lab tests. But todays opportunity comes from overenergetic market correction. A week ago I highlighted BGNE as the most opportune biotech stock for near-term capital gain. Forecast: 22 up, maybe -14 on the way getting there. 